News & Updates
Filter by Specialty:
Genotype-guided platelet inhibition improves STEMI outcomes
Bedside genotype testing for mutations in the CYP2C19 gene helps select a better P2Y12 inhibitor treatment strategy for patients with ST-segment elevation myocardial infarction (STEMI) and leads to better outcomes relative to conventional therapy, a recent study has found.
Genotype-guided platelet inhibition improves STEMI outcomes
22 Oct 2021
SGLT2i alone or with DPP4 inhibitors prevents hospitalization due to heart failure
Use of sodium glucose co-transporter 2 inhibitors (SGLT2is) either alone or in combination with dipeptidyl peptidase 4 inhibitors (DPP4is) reduces the risk of hospitalization from heart failure (HHF), a study has shown. In contrast, thiazolidinediones alone or in combination with DPP4is increases HHF risk, but glucose-lowering can help reduce HHF.
SGLT2i alone or with DPP4 inhibitors prevents hospitalization due to heart failure
21 Oct 2021
PCI yields short-term mortality gains in STEMI patients receiving dialysis
Primary percutaneous coronary intervention (pPCI) is as good as conservative management in terms of the benefit for in-hospital mortality among ST-segment elevation myocardial infarction (STEMI) patients receiving maintenance dialysis, a study has found.
PCI yields short-term mortality gains in STEMI patients receiving dialysis
21 Oct 2021
DOACs on par with LMWH at preventing VTE in cancer patients
Cancer patients receiving either low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) show comparable frequency of venous thromboembolism (VTE), reports a recent study.
DOACs on par with LMWH at preventing VTE in cancer patients
19 Oct 2021
Warfarin plus aspirin tied to higher bleeding risk than monotherapy in AF patients
The combination of aspirin and warfarin therapy appears to increase the risk of bleeding, with little benefit in reducing stroke or cardiovascular events compared with warfarin alone in patients with atrial fibrillation (AF), reveals a study.
